Research paper

25-Hydroxycholesterol and 27-hydroxycholesterol inhibit human rotavirus infection by sequestering viral particles into late endosomes

Andrea Civra, Rachele Francese, Paola Gamba, Gabriella Testa, Valeria Cagno*, Giuseppe Poli*, David Lembo*

Department of Clinical and Biological Sciences, University of Turin, Regione Console 10, 10043 Orbassano, TO, Italy

A B S T R A C T

A novel innate immune strategy, involving specific cholesterol oxidation products as effectors, has begun to reveal connections between cholesterol metabolism and immune response against viral infections. Indeed, 25-hydroxycholesterol (25HC) and 27-hydroxycholesterol (27HC), physiologically produced by enzymatic oxidation of cholesterol, act as inhibitors of a wide spectrum of enveloped and non-enveloped human viruses. However, the mechanisms underlying their protective effects against non-enveloped viruses are almost completely unexplored. To get insight into this field, we investigated the antiviral activity of 25HC and 27HC against a non-enveloped virus causing acute gastroenteritis in children, the human rotavirus (HRV). We found that 25HC and 27HC block the infectivity of several HRV strains at 50% inhibitory concentrations in the low micromolar range in the absence of cell toxicity. Both molecules affect the final step of virus penetration into cells by preventing the association of two cellular proteins: the oxysterol binding protein (OSBP) and the vesicle-associated membrane protein-associated protein-A (VAP-A). By altering the activity of these cellular mediators, 25HC and 27HC disturb the recycling of cholesterol between the endoplasmic reticulum and the late endosomes which are exploited by HRV to penetrate into the cell. The substantial accumulation of cholesterol in the late endosomal compartment results in sequestering viral particles inside these vesicles thereby preventing cytoplasmic virus replication. These findings suggest that cholesterol oxidation products of enzymatic origin might be primary effectors of host restriction strategies to counteract HRV infection and point to redox active lipids involvement in viral infections as a research area of focus to better focus in order to identify novel antiviral agents targets.

Introduction

Innate immune response is the first line of defense during the earliest hours of exposure to a novel pathogen. Its mechanisms are non-specific and rely on a group of proteins and phagocytic cells that quickly activate to help destroy invaders. Alongside these pathways, a novel innate immune strategy has begun to reveal connections between cholesterol metabolism and immune response against viral infections [1–5].

The most widely studied effector of this branch of innate immunity is an oxysterol, 25-hydroxycholesterol (25HC) [1,2]. Oxysterols contain 27 carbon atoms per molecule and are derived from cholesterol by both enzymatic and nonenzymatic oxidation [4–6]. Several among the various cholesterol oxidation products of enzymatic origin contribute to physiological functions: they are intermediates of pregnenolone and steroid hormone synthesis [7] and target nuclear receptors (e.g., the liver X receptor [LXR] and the estrogen receptor α [ER α]), cellular membrane receptors (e.g., C-X-C motif chemokine receptor 2 [CXCR2]) and transport proteins (e.g., insulin induced gene protein [INSIG], Niemann-Pick protein 1 [NPC1], oxysterol binding protein [OSBP] and its related proteins [ORPs]) [8–13]. In contrast, the oxysterols derived from cholesterol autoxidation, a not-regulated and therefore potentially harmful biochemical reaction, appear to be more likely involved in pathophysiological processes associated with inflammation and oxidative stress [4,5,14].

In 2013 Blanc and colleagues provided in vitro findings indicating that 25HC acts as a physiological interferon (IFN)-induced effector of innate immunity against viral infections [1]. They reported that 25HC was the only oxysterol synthesized and secreted by macrophages upon IFN treatment or virus infection and that transcription factor Stat1 directly couples IFN-stimulated signaling to regulation of the cholesterol hydroxylase gene (Ch25h) encoding the 25HC-synthesizing enzyme.

Unlike known antiviral small molecules that target highly specific viral determinants, thus showing a restricted spectrum of activity, 25HC inhibits the replication of a wide spectrum of pathogenic viruses. This includes both enveloped viruses, i.e., those with a phospholipidic bilayer outside the proteic capsid such as human immunodeficiency virus (HIV), herpes simplex virus type 1 (HSV-1), varicella zoster virus (VZV) murine cytomegalovirus (MCMV), vesicular stomatitis virus (VSV), Ebola virus (EBOV), Zika virus, hepatitis C virus, and...
orthomixovirus [1,2,15–19], and non-enveloped viruses such as human rhinovirus (HRV) [20–22], human papillomavirus (HPV), and human rotavirus (HRV) [21].

This unprecedented range of antiviral properties is ascribable to the ability of 25HC to modulate cellular lipid metabolism and transport, thereby modifying the composition and structure of cellular and subcellular membranes [23,24]. Since viral pathogens have to pass through cellular lipid membranes or hijack them to assemble their replicative machinery, regulation of the lipid composition of cellular and subcellular membranes looks like a particularly smart and effective strategy to counteract viral invasion from a strictly evolutionary point of view.

The mechanisms underlying the antiviral activity of 25HC have been extensively investigated for a number of enveloped viruses: 25HC might alter the lipid composition of cellular membranes, thus hampering the fusion between the viral envelope and the cytoplasmic lipid bilayer that allows some enveloped viruses to penetrate into the host cell [1]. This oxysterol directly changes cell membrane properties by inserting itself into the lipid bilayer [2]. Moreover, various studies on 25HC-induced host response to HCV infection clearly correlated this protective action with an imbalance in the mevalonate pathway by the oxysterol [17,25–27], implying the inhibition of cholesterol synthesis and depletion of non-sterol isoprenoid products, in this way impairing cholesterol membrane content and protein prenylation [17,25–28]. Of note, our group showed that 25HC but also a second enzymatically synthesized oxysterol, 27-hydroxycholesterol (27HC) can stimulate the release of interleukin 6 (IL6) and are endowed with an anti-HSV-1 activity which is apparently non-unrelated to the viral entry inhibition [19].

By contrast, the mechanisms underlying the protective effects of cholesterol oxidation products against non-enveloped viruses are largely unexplored, with the unique exception of HRBlV [22] and 25HC as the only oxysterol examined so far [22]. In fact, this oxysterol has been shown to markedly reduce the accumulation of phosphatidylinositol 4-phosphate (P14P) in the Golgi apparatus, a crucial event for the assembly of HRBlV replicative machinery, by targeting members of the OSBP family I [20,22].

With regard to non-enveloped viruses, we previously described the antiviral activity exerted by 25HC and 27HC, particularly against HRV [21]. We investigated the mechanism of action of 25HC and 27HC against HRV to shed a light on an almost totally unexplored scenario, which may hold promise to reveal novel antiviral mechanisms and targets, likely exploitable for a new generation of antiviral molecules.

HRV belongs to the reoviridae family and represents one of the orthoreovirus, HRV belongs to the reoviridae family and represents one of the

Table 1

| Oxyesters | HRV strain | EC50 (µM) – 95% CI | EC90 (µM) – 95% CI | CC50 (µM) – 95% CI | SI |
|-----------|------------|-------------------|-------------------|-------------------|----|
| 25HC      | Wa         | 0.16 (0.12–0.20)  | 1.37 (0.75–2.40)  | > 150             | > 938 |
|           | W161       | 0.09 (0.08–0.12)  | 0.28 (0.16–0.46)  | > 150             | > 1667 |
|           | HRV408     | 0.12 (0.09–0.16)  | 0.42 (0.23–0.74)  | > 150             | > 1250 |
|           | HRV248     | 0.11 (0.07–0.18)  | 1.26 (0.47–3.38)  | > 150             | > 1364 |
|           | DS-1       | 0.27 (0.14–0.53)  | 5.77 (1.15–28.89) | > 150             | > 556  |
| 27HC      | Wa         | 0.26 (0.22–0.31)  | 1.73 (1.21–2.47)  | > 150             | > 577  |
|           | W161       | 0.19 (0.14–0.27)  | 0.74 (0.35–1.55)  | > 150             | > 790   |
|           | HRV408     | 0.40 (0.26–0.62)  | 4.56 (1.62–12.82) | > 150             | > 375   |
|           | HRV248     | 0.23 (0.12–0.46)  | 3.84 (0.80–18.39) | > 150             | > 652   |
|           | DS-1       | 0.72 (0.49–1.06)  | 5.85 (2.43–14.06) | > 150             | > 208   |

n.a. not assessable.

a EC50 half-maximal effective concentration.
b CI confidence interval.
c EC9090% effective concentration.
d CC50 half maximal cytotoxic concentration

Anti-HRV effect of 25HC and 27HC and their spectrum of activity

In a previous study, we reported on the inhibitory activity of 25HC and 27HC against the Wa strain of HRV [21]. To explore the spectrum of anti-HRV activity, 25HC and 27HC were tested against four additional HRV strains (W161, HRV 408, HRV 248, DS-1) in MA104 cells. As shown in Table 1, the antiviral activity of both 25HC and 27HC is not strain-restricted, with EC50 values falling in the low micromolar range and favorable selectivity index (SI) for all the HRV strains tested. Both oxysterols inhibited HRV infectivity to a maximum of 90% even at high MOI (MOI > 1000) (Fig. 3). Finally, 25HC and 27HC were also tested against HRV strain-restricted, with EC50 values falling in the low micromolar range and favorable selectivity index (SI) for all the HRV strains tested. Both oxysterols inhibited HRV infection in a dose-dependent fashion (Fig. 1). The antiviral potency of 25HC was significantly (p< 0.001) higher than that of 27HC against each strain tested. Since most of the assays of the mechanism of action described below were performed by testing 25HC and 27HC against high viruses/target cell ratios (MOI, multiplicity of infection), we verified that both molecules were able to inhibit HRV infectivity also under these conditions. Indeed, they significantly inhibited HRV infectivity to a maximum of 90% even at high MOI (MOI 10) (Fig. 3). Finally, 25HC and 27HC were also tested against HRV infection of human intestinal Caco2 cell line to determine whether their antiviral activity was influenced by the cellular model. The two oxysterols displayed a strong antiviral effect in both MA104 and Caco2 cells, two quite different cellular models (Tables 1 and 2; Figs. 1 and 2), thus indicating that their activity is not cell line dependent.
25HC and 27HC inhibit HRV-cell penetration

Specific assays were performed to identify which step(s) of the HRV replicative cycle was inhibited by the two oxysterols. Time-of-addition assays showed that 25HC and 27HC exerted their highest antiviral efficacy when added to cells 20 h before infection (Fig. 4A-B). By contrast, when the treatment was performed after viral infection, no antiviral effect was observed. These data suggest that both oxysterols modify the cellular milieu so as to render the cells less susceptible to HRV most likely by targeting cellular determinants essential for virus infection.

**Table 2**

| Oxysterols | HRV strain | EC50 (µM) – 95% CI | EC90 (µM) – 95% CI | CC50 (µM) – 95% CI | SI³ |
|------------|------------|------------------|------------------|------------------|-----|
| 25HC       | Wa         | 0.19 (0.14-0.25) | 1.26 (0.61-2.66) | > 150            | > 789|
|            | W161       | 0.25 (0.20-0.31) | 0.83 (0.50-1.38) | > 150            | > 600|
|            | HRV408     | 0.42 (0.36-0.48) | 2.30 (1.66-3.18) | > 150            | > 357|
|            | HRV248     | 0.21 (0.16-0.28) | 1.04 (0.55-1.94) | > 150            | > 714|
|            | DS-1       | 0.43 (0.29-0.63) | 2.42 (1.04-5.63) | > 150            | > 349|
| 27HC       | Wa         | 0.44 (0.34-0.56) | 2.50 (1.45-4.29) | > 150            | > 341|
|            | W161       | 0.34 (0.22-0.53) | 2.43 (0.90-6.59) | > 150            | > 441|
|            | HRV408     | 0.81 (0.66-1.09) | 3.78 (1.94-7.36) | > 150            | > 185|
|            | HRV248     | 0.41 (0.35-0.48) | 2.70 (1.90-3.83) | > 150            | > 366|
|            | DS-1       | 0.45 (0.34-0.61) | 2.62 (1.37-5.03) | > 150            | > 333|

n.a. not assessable.

*a* EC50 half-maximal effective concentration.

*b* CI confidence interval.

*c* EC90 90% effective concentration.

*d* CC50 half maximal cytotoxic concentration.

*e* SI selectivity index.
penetration or replication. Of note, as displayed in
Fig. 4C, the indirect immunocytochemistry clearly shows that no deposition of neo-synthe-
sitized HRV antigen occurs in both MA104 and Caco2 cells at 20 h post
infection, when infection was stopped by
fixing cells. Taken together,
these results suggested that 25HC and 27HC were able to affect the
steps of the HRV replicative cycle occurring before HRV protein
synthesis. For this reason, we investigated the e
ff
ect of oxysterols on the
earliest steps of HRV replication, i.e. virus binding and penetration.

Binding assay experiments clearly showed that treatment with both
25HC and 27HC had no e
ff
ect on HRV attachment to the cell surface
(Fig. 5 panel A).

In a second set of experiments, we assessed the ability of the oxy-
sterols to alter HRV entry kinetics into the cells. Both 25HC and 27HC
signi
fi
cantly (0.001 < pANOVA < 0.05) hampered normal virus-cell
penetration, when measured as a function of viral particles that enter
cells and carry out a single replication cycle (Fig. 5B). Consistent with
previous results (Fig. 1), 25HC affected HRV entry kinetics more po-
tently than 27HC.

HRV penetration into the host cell is a complex event involving re-
ceptor-mediated endocytosis, LE membrane permeabilization, and release
of the virus particle into the cytoplasm where viral replication occurs.

Interestingly, when we forced by means of Lipofectamine the infection of
an ethylene glycol tetraacetic acid (EGTA)-inactivated HRV suspension,
thereby bypassing viral entry through endocytosis, 25HC and 27HC
showed no antiviral activity (Fig. 5C). Consistently with these results,
when we added oxysterols on infected cells after NH4Cl treatment (i.e.
after the HRV exit from LEs) no antiviral activity was measurable
(Fig. 5D). More importantly, we analyzed the intracellular localization of
HRV 8 h post-inoculum, when most of the virus particles have already
escaped from the LEs and replicate in the cytoplasm where newly syn-
thesized viral proteins accumulate. As expected, confocal immune mi-
croscopy revealed that the viral antigen VP6 was mostly di
ff
used in the
cytoplasm of untreated infected cells (Fig. 6). By contrast, in both the
25HC- and the 27HC-treated cells, almost all VP6 co-localized with a
marker of LEs (Rab-7). Taken together, these results indicate that 25HC
and 27HC affect HRV entry by sequestering the virus particles penetrating
the LEs and preventing their replication in the cytoplasm.
OSBP and VAP-A are cellular determinants of 25HC and 27HC anti-HRV activity

To elucidate the mechanism by which 25HC and 27HC block HRV penetration in the LEs, we focused our attention on the cellular protein OSBP, one of the main intracellular interactors of oxysterols. Proteins that prevent OSBP association with the vesicle-associated membrane protein-associated protein A (VAP-A) are known to disrupt intracellular cholesterol homeostasis, leading to cholesterol accumulation on the LEs membrane. This event has been shown to inhibit the entry of specific enveloped viruses [38,39]. Although this mechanism has been postulated only for enveloped viruses, we hypothesized that the model of a "greasy response" to viral infection - as defined by Tanner and colleagues in 2013 [39] - could fit with our results (Fig. 6). In specific assays to verify whether this mechanism applies to the anti-HRV activity of oxysterols, first we used co-immunoprecipitation assays to assess whether physical interaction between OSBP and VAP-A was disrupted in 25HC- or 27HC-treated MA104 cells.

Immunoprecipitation of VAP-A co-immunoprecipitated OSBP in untreated cells and the reverse was demonstrated (Fig. 7A). Co-immunoprecipitation was specific since neither VAP-A nor OSBP was detected in the immunoprecipitates obtained with an unrelevant antibody used as a negative control. This result was consistent with previous studies that showed a physical interaction between OSBP and VAP-A. Interestingly, we found that the association of OSBP to VAP-A was disrupted in the 25HC- or 27HC-treated cells. Control experiments showed that the treatment did not down-regulate OSBP and VAP-A protein levels (Fig. 7B). To explore whether OSBP and VAP-A play a role in the antiviral activity exerted by 25HC or 27HC, we performed target identification by siRNA sensitization (TISS) assay. This assay allows to evaluate whether knockdown of OSBP or VAP-A results in enhanced sensitivity to suboptimal concentrations of 25HC or 27HC.

Silencing of the expression of both proteins by specific siRNA improved the antiviral efficacy of both 25HC and 27HC (Fig. 8A-B-D-E). By contrast, no effect was observed when the cells were transfected with a non-targeting siRNA. A slight but significant (pANOVA < 0.01) block of HRV infectivity was measurable in the OSBP- and VAP-A-silenced untreated cells (Fig. 8C-F). Taken together, these results prove that OSBP and VAP-A are cellular determinants of the anti-HRV activity elicited by 25HC and 27HC.

25HC and 27HC induce cholesterol accumulation in LEs

We next investigated by confocal immunomicroscopy whether treatment of MA104 cells with 25HC or 27HC induces cholesterol accumulation in LEs. As a positive control, cells were treated with U18666A, an amphipathic steroid 3-β-[2-(diethylamine)ethoxy] androst-5-en-17-one that blocks the exit of free cholesterol from the LE compartment. Cholesterol accumulation was visualized by filipin, a fluorescent polyene antibiotic that binds to cholesterol but not to esterified sterols. As compared to the untreated cells, cholesterol accumulation was observed in the LEs of the cells treated with the oxysterols or U18666A, along with enlargement of the LE compartment (Fig. 9). Like 25HC and 27HC, U18666A was found to be endowed with anti-
HRV activity (Table 3; Fig. 10A, B, C, D, E), even when the cells were infected with high MOIs (Fig. 10F), it was not endowed with antiviral activity when added after HRV escape from LEs (Fig. 10G), when cells were infected with an HRV suspension that skipped the endocytosis steps (Fig. 10H), and it blocked the viruses penetrating inside the LEs (Fig. 10I).

Discussion

Here we show that 25HC and 27HC sequester HRV Wa inside LEs and that both are endowed with antiviral activity against the LEs-dependent strains Wa, WI61, and DS-1, as well as against strains HRV248 and HRV408. Physiologic concentrations of 25HC and 27HC range from...
A recent study by Amini-Bavil-Olyaee and colleagues investigating OSBP/VAP-A-mediated cholesterol shuttling as a cellular restriction mechanism of innate immunity against enveloped viruses showed that interferon-inducible transmembrane protein 3 (IFITM3) expression induces substantial accumulation of cholesterol within LE compartments in a VAP-A binding dependent manner [38]. IFITM3 was found to interact with VAP-A and prevent its association with OSBP, so inducing a marked accumulation of cholesterol in multivesicular bodies and LEs; the latter event inhibited the fusion of intraluminal virion-containing vesicles with endosomal membranes, thereby blocking virus release into the cytosol of IAV and VSV.

To this end, Tanner and Lee commented on a novel and intriguing antiviral mechanism they called “the greasy response” to viral infections: IFITM3 expressed at LE compartments interacts with VAP-A and disrupts the ER resident complex between OSBP and VAP-A, leading to cholesterol accumulation in LE, thus blocking virus entry [39]. An eventual involvement of oxysterol (the highest affinity ligands of OSBP) was never demonstrated.

In the present study, we demonstrate for the first time that oxysterols can trigger this antiviral mechanism, and that this restriction strategy can block the infectivity of a non-enveloped virus. Consistent with previous data showing 25HC-induced translocation of OSBP from the ER (where VAP-A is localized) to the Golgi [49], we show that treatment with 25HC prevents the association of OSBP to VAP-A. More interestingly, we report that even 27HC can abolish OSBP-VAP-A interaction. Accordingly, both 25HC and 27HC appeared to induce a substantial accumulation of cholesterol in the LE compartment.

In agreement with our initial hypothesis, the antiviral effect of oxysterols was potentiated in the cells in which the expression of either OSBP or VAP-A was silenced. The silencing of these proteins in the untreated cells exerted a partial block of HRV infectivity, thus stressing the involvement of these two proteins in HRV replication.

The present report also provides proof of concept that accumulation of cholesterol within LEs is an effective anti-HRV mechanism. While many studies have demonstrated the wide spectrum of antiviral activity of U18666A against enveloped viruses [50–52], we provide the first evidence of its antiviral potential against a non-enveloped virus. This cationic amphiphile causes a significant block of HRV infectivity even at high MOIs by inducing cholesterol accumulation on LEs and sequestering HRV inside them. This finding opens the way to the search for small anti-HRV molecules endowed with this molecular mechanism.

Cholesterol accumulation on the membrane of LEs leads to several dramatic modifications of this intracellular compartment. Our results show that cholesterol accumulation in the larger cholesterol-enriched LEs in the 25HC-, 27HC-, and U18666A-treated cells leads to enlargement of LEs. Moreover, Sobo and colleagues showed that cholesterol accumulation dramatically perturbs the back fusion of intraluminal vesicles with the limiting membrane and intra-organellar trafficking [53]. Inhibition of back fusion events is expected to severely interfere with the sorting and trafficking of the proteins that cycle between intraluminal and limiting membranes, as was shown for the cdn-dependent mannose-6-phosphate receptor (CD-M6PR; 53). LE-dependent HRVs are strictly dependent on the presence of the CD-M6PR on such vesicles to become uncoated and exit the endosomal system [37]. These cholesterol-induced perturbations of the LE compartment provide a reasonable explanation for why cholesterol accumulation blocks HRV particles inside these organelles.

In conclusion, both 25HC and 27HC appear to exert a remarkable anti-HRV effect, based at least on the impairment of the OSBP/VAP-A interplay and on abnormal cholesterol accumulation within LEs, the last gate for the virus to enter the cytosol. Indeed, since these side chain oxysterols have been shown to drive a number of biochemical reactions within the cells [14], their direct action on LE structure and function cannot be excluded.

This study discloses a totally novel mechanism of two oxysterols of enzymatic origin suggesting that, besides 25HC, other members of this
family could be actively involved in the innate immunity response against viruses. To these end, our results demonstrate that lipid involvement as host restriction strategy is an area of focus which, with the recent advances in technology, holds great promise to discover novel mechanisms and redox active lipid factors to develop innovative approaches for antiviral therapy.

Fig. 8. Effect of OSBP silencing (panels A, B, and C) or VAP-A silencing (panels D, E, and F) by short interfering RNA (siRNA) transfection on the antiviral activity of 25HC or 27HC. Cells were transfected for 72 h with 20 nM of anti-OSBP siRNA, anti-VAP-A siRNA or control non-interfering siRNA. Cells were then treated for 20 h with oxy-sterols at sub-optimal concentrations and finally infected with HRV Wa. Viral infections were detected as described in the Material and Methods section. The infectivity titers of virus in the treated samples are expressed as a percentage of the titer obtained in the absence of treatment. Error bars represent the standard error of the mean (SEM) of 3 independent experiments. *pANOVA < 0.05; **pANOVA < 0.01; ***pANOVA < 0.001.
Fig. 9. Effect of 25HC or 27HC on intracellular localization of cholesterol. Positive control experiments were performed by treating cells with U18666A. Treated or untreated MA104 were fixed at 20 h post-treatment and intracellular cholesterol was stained with filipin (blue signal) and late endosomes with anti-Rab7 antibody (green signal). The inserts in the right panels show the merged signals.

Table 3
Antirotavirus activity of U18666A (MA104 cells).

| Treatment | HRV strain | EC50 (µM) – 95% CI | EC90 (µM) – 95% CI | CC50 (µM) -95% CI | SI |
|-----------|------------|-------------------|-------------------|------------------|----|
| U18666A   | Wa         | 1.44 (1.17–1.78)  | 11.66 (7.63–17.83)| 219.3 (180.6–266.4) | 152.29 |
|           | Wi61       | 7.84 (7.08–8.68)  | 20.89 (16.72–26.09)| 219.3 (180.6–266.4) | 27.97 |
| HRV408    | 2.14 (1.55–2.95) | 12.04 (5.94–24.42)| 219.3 (180.6–266.4) | 102.47 |
| HRV248    | 2.63 (1.74–3.80) | 17.60 (7.05–43.94)| 219.3 (180.6–266.4) | 83.38 |
| DS-1      | 5.84(4.76–7.16) | 19.87 (12.43–31.74)| 219.3 (180.6–266.4) | 37.56 |

n.a. not assessable.

* EC50 half-maximal effective concentration.

* CI confidence interval.

* EC90 90% effective concentration.

* CC50 half maximal cytotoxic concentration.

* SI selectivity index.
Fig. 10. Assessment of the antiviral activity of U18666A against HRV strains and assessment of its mechanism of action. Cells were treated for 20 h with increasing concentrations of U18666A and then infected with HRV Wa (A), W161 (B), HRV 248 (C), DS-1 (D), and HRV 408 (E). Viral infections were detected as described in the Material and Methods section. The percentage infection was calculated by comparing treated and untreated wells. The results are means and SEM for triplicates.***pANOVA < 0.001. Panel F: cells were treated with 1.9 µM of U18666A for 20 h, then infected with high multiplicities of infection (MOIs) of HRV Wa. The percentage infection was calculated by comparing treated and untreated wells. The results are means and SEM for triplicates.**pANOVA < 0.01. Panel G: effect of oxysterols when added after HRV escape from LEs. Cells were infected for 45 min, treated with 25 mM of NH₄Cl for 15 min, then oxysterols were added. Panel H: effect of oxysterols on the infectivity of EGTA-inactivated HRV Wa transfected with lipofectamine (black bars) or trypsin-activated HRV Wa (white bars). MA104 cells were treated 20 h before inoculums. * **pANOVA < 0.001 Panel I: intracellular localization of HRV VP6 antigen as assessed by immunofluorescence experiments. Infected MA104 were fixed at 8 h post-infection and stained with anti-VP6 antibody (red signal) and anti-Rab7 antibody (green signal). The inserts in the right panels show the merged signals.
Materials and methods

Cell line and viruses

African green monkey kidney epithelial cells (MA104) and human epithelial colorectal adenocarcinoma cells (Caco-2) were propagated in Dulbecco’s Modified Eagle Medium (DMEM; Sigma, St. Louis, MO, USA) supplemented with 1% (v/v) Zell Shield (Minerva Biolabs, Berlin, Germany) and heat inactivated, 10% (v/v) fetal bovine serum (Sigma). Human rotavirus (HRV) strains Wa (ATCC VR-2018), Wi61 (ATCC VR-2551), HRV 408 (ATCC VR-2273), HRV 248 (ATCC VR-2274), DS-1 (ATCC VR-2550) were purchased from ATCC (American Type Culture Collection, Rockville, MD, USA); virus was activated with 5 µg/ml of porcine pancreatic trypsin type IX (Sigma) for 30 min at 37 °C and propagated in MA104 cells using DMEM containing 0.5 µg of trypsin per ml as described previously [54]. Viral titers are expressed as focus-forming unit (FFU) per ml.

Antibodies and reagents

25HC and 27HC (Sigma) were dissolved in sterile ethanol at concentrations ranging from 2.75 mM to 3 mM. U18666A was purchased from Millipore (Darmstadt, Germany) and dissolved in sterile dimethyl sulfoxide (DMSO) to a concentration of 5 mM. Mouse monoclonal antibody (mAb) directed to human rotavirus VP6 (2B4) was purchased from Covalab (Villeurbanne, France). The rabbit polyclonal antibodies directed to VAP-A (H-40: sc-98890) and Rab 7 (H-50: sc-10767) were purchased from Santa Cruz Biotechnology, Inc. (Dallas, TX, USA). The rabbit polyclonal antibody directed to OSBP (C2C3) was purchased from Santa Cruz Biotechnology, Inc. (Dallas, TX, USA). The rabbit polyclonal antibody directed to OSBP-N-terminal (ab192990) was purchased from Abcam (Cambridge, UK). The mouse monoclonal antibody directed to actin (MA1501R) was purchased from Millipore. The secondary antibody peroxidase-conjugated AffiniPure F(ab’)2 Fragment Goat Anti-Mouse IgG (H+L) was purchased from Jackson ImmunoResearch Laboratories Inc. (West Grove, PA, USA). The secondary antibodies anti-mouse IgG horseradish (HRP)-linked (NA931V) and anti-rabbit IgG HRP-linked (NA934V) were purchased from GE Healthcare UK (Chalfont St Giles, UK). The secondary antibodies goat anti-rabbit IgG-FITC (sc-2012) and goat anti-mouse IgG-R (sc-2092) were purchased from Santa Cruz Biotechnology, Inc.

Antiviral assays

The antiviral efficacy of the oxysterols was determined by focus reduction assay on confluent MA104 or Caco2 cell monolayers plated in 96-well trays, as described elsewhere [21]. Cells were treated for 20 h at 37 °C with 25HC, 27HC or U18666A at concentrations ranging from 0.07 to 16.7 mM (corresponding to 28.2 and 60400 µg/L for both oxysterols, and 29.7 and 63609 µg/L for U18666A) to generate dose-response curves. Control samples (100% of viability) were prepared by treating cells with culture medium supplemented with equal volumes of ethanol, corresponding to 0.6% (v/v) to 0.0025% (v/v) in cell media. After 24 h of incubation, cell viability was determined using a CellTiter 96 Proliferation Assay Kit (Promega, Madison, WI, USA) and following the manufacturer’s instructions. Absorbances were measured using a Microplate Reader (Model 680, Bio-Rad Laboratories, Hercules, CA, USA) at 490 nm. Viability of oxysterol-treated cells is expressed as a percentage relative to cells incubated with culture medium supplemented with equal volumes of ethanol.

Rotavirus-cell binding assay

Rotavirus-cell binding assays were performed as described previously [54]. Confluent MA104 cell monolayers in 24-well trays were treated with 25HC or 27HC at 1.8 mM or 5.6 µM. After 20 h, cells were washed with fresh medium and cooled on ice. Trypsin-activated virus, which had been cooled to 4 °C, was allowed to attach to cells for 1 h (MOI = 3 FFU/cell) at 4 °C. After a washing with cold DMEM, the cells were subjected to two rounds of freeze-thawing and then incubated at 37 °C for 30 min with 10 µg/ml porcine trypsin to release bound virus. The lysates were clarified by low speed centrifugation for 10 min. Cell-bound virus titers were determined by indirect immunostaining as above.

Rotavirus-cell entry assay

Confluent MA104 cell monolayers in 96-well plates were treated with 25HC or 27HC at concentrations ranging from 0.07 to 16.7 µM. After 20 h, cells were washed twice with DMEM and cooled on ice for 20 min. Trypsin-activated virus, which had been cooled to 4 °C, was adsorbed to cells on ice for 1 h at 4 °C (MOI = 0.2 FFU/cell) to ensure virus attachment but not entry. Unbound viruses were then washed, warmed medium was added, and the plates were incubated at 37 °C in humidified atmosphere to allow entry. At fixed timepoints (0, 15, 30, 45, 60, 75, 90 min after virus-cell attachment), the medium in the wells was aspirated, and viral particles still present on the cell surface were detected by two quick washes with 3 mM EGTA in PBS, followed by incubation in warm medium. After reaching the last timepoint (90 min), the plates were placed into a CO2 incubator, and the infection was left to proceed for an additional 16 h. The cells were then fixed and stained by indirect immunostaining as described above. The amount of virus that entered at each time point was compared to the amount of virus that entered when no EGTA wash was performed, which was taken as 100% entry.
PCR was performed with 30 ng of cDNA using TaqMan Gene Expression cDNA Reverse Transcription Kit (Applied Biosystems). Quantitative RT-PCR was performed with 30 ng of cDNA using TaqMan Gene Expression cDNA Reverse Transcription Kit (Applied Biosystems). Concentration and purity of the extracted RNA were assessed by spectrophotometry (A260/A280). Later, 2 µg of RNA were reverse transcribed by using a High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems). Quantitative RT-PCR was performed with 30 ng of cDNA using TaqMan Gene Expression cDNA Reverse Transcription Kit (Applied Biosystems). Concentration and purity of the extracted RNA were assessed by spectrophotometry (A260/A280). Later, 2 µg of RNA were reverse transcribed by using a High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems). Concentration and purity of the extracted RNA were assessed by spectrophotometry (A260/A280). Later, 2 µg of RNA were reverse transcribed by using a High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems). Quantitative RT-PCR was performed with 30 ng of cDNA using TaqMan Gene Expression cDNA Reverse Transcription Kit (Applied Biosystems). Concentration and purity of the extracted RNA were assessed by spectrophotometry (A260/A280). Later, 2 µg of RNA were reverse transcribed by using a High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems). Quantitative RT-PCR was performed with 30 ng of cDNA using TaqMan Gene Expression cDNA Reverse Transcription Kit (Applied Biosystems). Concentration and purity of the extracted RNA were assessed by spectrophotometry (A260/A280). Later, 2 µg of RNA were reverse transcribed by using a High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems). Quantitative RT-PCR was performed with 30 ng of cDNA using TaqMan Gene Expression cDNA Reverse Transcription Kit (Applied Biosystems). Concentration and purity of the extracted RNA were assessed by spectrophotometry (A260/A280). Later, 2 µg of RNA were reverse transcribed by using a High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems). Quantitative RT-PCR was performed with 30 ng of cDNA using TaqMan Gene Expression cDNA Reverse Transcription Kit (Applied Biosystems). Concentration and purity of the extracted RNA were assessed by spectrophotometry (A260/A280). Later, 2 µg of RNA were reverse transcribed by using a High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems). Quantitative RT-PCR was performed with 30 ng of cDNA using TaqMan Gene Expression.
human immunodeficiency virus replication in vitro, Antivir. Chem. Chemother. 9 (1998) 491–496.

[16] E.S. Gold, A.H. Diercks, I. Podołsky, R.L. Podmynogin, P.S. Askovich, P.M. Treuting, A. Aderem, 25-Hydroxycholesterol acts as an amplifier of inflammatory signaling, Proc. Natl. Acad. Sci. USA 111 (2014) 10666–10671.

[17] A.I. Su, J.P. Pezacki, L. Wodicka, A.D. Brudie, L. Supekoova, R. Thimme, S. Wieland, J. Bukh, R.H. Purcell, P.G. Schultz, F.V. Chisari, Genomic analysis of the host response to hepatitis C virus infection, Proc. Natl. Acad. Sci. USA 99 (2002) 15669–15674.

[18] M. Iwamoto, K. Watashi, S. Tsukuda, H.H. Aly, M. Fukasawa, A. Fujimoto, R. Suzuki, H. Aiakizi, T. Ito, O. Koivu, H. Kusuhara, T. Wataki, Evaluation and identification of hepatitis B virus entry inhibitors using HepG2 cells overexpressing a membrane transporter NTCP, Biochem. Biophys. Res. Commun. 443 (2014) 808–813.

[19] V. Cagno, A. Civra, D. Rosin, S. Calfapietra, C. Caccia, V. Leon, N. Dorma, E.R. Mackow, H.B. Greenberg, Identification of a rhesus rotavirus binding glycoprotein on murine enterocytes, Virology 183 (1991) 602–610.

[20] C.D. Kirkwood, R.F. Bishop, B.S. Coupland, Attachment and growth of human rotavirus RV-3 and S12/85 in Caco-2 cells depend on VP4, J. Virol. 72 (1998) 9346–9352.

[21] M.A. Diaz-Salinas, D. Silva-Ayala, C.F. Arias, Rotavirus reaches late endosomes and requires the cation-dependent mannose-6-phosphate receptor and the activity of cathepsin proteases to enter the cell, J. Virol. 88 (2014) 4389–4402.

[22] E.G. Settembre, J.Z. Chen, O.J. Parnham, S. Maffeo, A. Tani, A. Savelkoul, N. Grigoriev, Y. Wu, S.O. Sow, D. Sur, R.F. Breiman, A.S. Faruque, A.K. Zaidi, D. Saha, Ebola virus entry, PLoS Pathog. 14 (2018) e1006820.

[23] M. Lakadamyali, M.J. Rutt, X. Zhang, Endocytosis of influenza viruses, Microbes Infect. 6 (2004) 929–936.

[24] P.S. Roulin, M. Lötzerich, F. Torta, L.B. Tanner, F.J. van Kuppeveld, M.R. Wenk, R. Suzuki, H. Aizaki, T. Ito, O. Koiwai, H. Kusuhara, T. Wakita, Evaluation and identification of hepatitis B virus entry inhibitors using HepG2 cells overexpressing a membrane transporter NTCP, Biochem. Biophys. Res. Commun. 443 (2014) 808–813.

[25] S.N. Pattanakitakul, J. Poungswai, R. Kanlaya, S. Sinchaiwit, S.C. Chen, V. Thongboonkerd, Association of Alis with late endosomal lysobiphosphatic acid is important for dengue virus infection in human endothelial cells, J. Proteome Res. 9 (2010) 4640–4648.

[26] A. Lebo, V.M. Olikkosen, The OSI8B-related proteins: a novel family protein involved in vesicle transport, cellular lipid metabolism, and cell signalling, Biochim. Biophys. Acta 2003 (1631) 1–11.

[27] W.A. Franza, Non-vesicular sterol transport in cells, Prog. Lipid Res. 46 (2007) 297–314.

[28] M.H. Ngo, T.R. Colbourne, N.D. Ridgway, Functional implications of sterol transport on the oxysterol-binding protein gene family, Biochem. J. 392 (2010) 13–24.

[29] T.P. Levine, S. Munro, Targeting of Golgi-specific pleckstrin homology domains involves both Phm 4 kinase-dependent and -independent components, Curr. Biol. 12 (2002) 695–704.

[30] T.P. Levine, S. Munro, The pleckstrin homology domain of oxysterol-binding protein recognizes a determinant specific to Golgi membranes, Curr. Biol. 8 (1998) 729–739.

[31] J.P. Nataro, W.C. Blackwelder, D. Nasrin, T.H. Farag, S. Panchalingam, L.M. Johansen, J.M. White, Multiple cationic amphiphiles induce a Niemann-Pick C phenotype and inhibit Ebola virus entry and infection, Plos One 8 (2013) e56265.

[32] C.J. Shoemaker, K.M. Schornberg, S.E. Delos, C. Seally, P.J. Houbrechts, G.G. Olinger, L.M. Johansen, J.M. White, Multiple cationic amphiphiles induce a Niemann-Pick C phenotype and inhibit Ebola virus entry and infection, Plos One 8 (2013) e56265.

[33] M.K. Poh, G. Shui, K. Xie, P.Y. Shi, M.R. Wenk, F. Gu, U18666A, an intracellular cholesterol transport inhibitor, inhibits dengue virus entry and replication, Antivir. Res. 93 (2012) 191–198.

[34] T. Takano, K. Tsukiyama-Kohara, M. Hayashi, Y. Hirata, M. Satoh, T. Tokunaga, C. Tateno, Y. Hayashi, T. Ishihama, N. Funata, M. Sudo, M. Kohara, Augmentation of DHR24 expression by hepatitis C virus infection facilitates viral replication in hepatocytes, J. Hepatol. 55 (2011) 512–521.

[35] K. Sobo, I. Le Blanc, P.P. Luyet, C. Fivaz, G. Ferguson, R.G. Parton, J. Gruenberg, F.G. van der Goot, Late endosomal cholesterol accumulation leads to impaired intra-endosomal trafficking, PLoS One 2 (2007) e851.

[36] A. Civra, M.G. Gruiffria, M. Donalisio, L. Napolitano, Y. Takada, B.S. Coupland, A. Conti, D. Lembo, Identification of equine lactadherin-derived peptides that in hibrit rotavirus infection via integrin receptor competition, J. Biomed. Chem. 290 (2015) 12403–12414.

[37] M. Gutierrez, P. Ica, C. Sanchez-San Martin, J. Perez-Vargas, R. Espinosa, C.F. Arias, S. Lopez, Different rotavirus strains enter MA104 cells through different endocytic pathways: the role of cation-mediated endocytosis, J. Virol. 84 (2010) 9161–9169.

[38] M. Soliman, J.Y. Seo, D.S. Kim, J.Y. Kim, J.G. Park, M.M. Alfajaro, Y.B. Baek, H.E. Cho, J. Kwon, J.S. Choi, M.J. Kang, S.I. Park, K.O. Cho, Activation of P38, Akt, and ERK during early rotavirus infection leads to V-ATPase-dependent endocytic acidification required for uncoating, PLoS Pathog. 14 (2018) e1006820.

[39] J.K. Livak, T.D. Schmittgen, Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta CT) method, Methods 25 (2001) 402–408.